Market closedNon-fractional
DexCom/DXCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About DexCom
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Ticker
DXCM
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
San Diego, United States
Employees
9,550
Website
www.dexcom.com
DexCom Metrics
BasicAdvanced
$43B
Market cap
70.18
P/E ratio
$1.54
EPS
1.21
Beta
-
Dividend rate
Price and volume
Market cap
$43B
Beta
1.21
Financial strength
Current ratio
2.898
Quick ratio
2.435
Long term debt to equity
114.358
Total debt to equity
115.28
Interest coverage (TTM)
32.10%
Management effectiveness
Return on assets (TTM)
6.79%
Return on equity (TTM)
28.54%
Valuation
Price to earnings (TTM)
70.18
Price to revenue (TTM)
10.975
Price to book
19
Price to tangible book (TTM)
20.32
Price to free cash flow (TTM)
71.507
Growth
Revenue change (TTM)
25.78%
Earnings per share change (TTM)
116.03%
3-year revenue growth (CAGR)
23.33%
3-year earnings per share growth (CAGR)
4.99%
What the Analysts think about DexCom
Analyst Ratings
Majority rating from 26 analysts.
DexCom Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$921M
-10.97%
Net income
$146M
-42.88%
Profit margin
15.89%
-35.85%
DexCom Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.34
$0.50
$0.50
$0.32
-
Expected
$0.23
$0.34
$0.43
$0.27
$0.39
Surprise
50.30%
46.74%
15.87%
18.50%
-
DexCom News
AllArticlesVideos
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of DexCom Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·2 hours ago
DexCom, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by DexCom (DXCM)
Accesswire·5 hours ago
Dexcom stock plummeting is an 'opportunity to add to positions', says Wolfe Research's Mike Polark
CNBC Television·5 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DexCom stock?
DexCom (DXCM) has a market cap of $43B as of July 27, 2024.
What is the P/E ratio for DexCom stock?
The price to earnings (P/E) ratio for DexCom (DXCM) stock is 70.18 as of July 27, 2024.
Does DexCom stock pay dividends?
No, DexCom (DXCM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next DexCom dividend payment date?
DexCom (DXCM) stock does not pay dividends to its shareholders.
What is the beta indicator for DexCom?
DexCom (DXCM) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell DexCom stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.